Tumor‐associated DNA mutation detection in individuals undergoing colonoscopy

• Published in: Cancer medicine (Malden, MA) MA), 2018-01, Vol.7 (1), p.167-174
• Main Authors: Fleshner, Phillip, Braunstein, Glenn D., Ovsepyan, Gayane, Tonozzi, Theresa R., Kammesheidt, Anja
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Cancer Biology; Circulating free DNA; circulating tumor DNA; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Colon; Colon - diagnostic imaging; Colon - pathology; Colonic Polyps - blood; Colonic Polyps - diagnosis; Colonic Polyps - genetics; Colonic Polyps - pathology; Colonoscopy; Colorectal cancer; Colorectal Neoplasms - blood; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; colorectal polyps; Deoxyribonucleic acid; DNA; Female; Humans; liquid biopsy; Male; Mass Screening - methods; Middle Aged; Mutation; Original Research; Polyps; Precancerous Conditions - blood; Precancerous Conditions - diagnosis; Precancerous Conditions - genetics; Prospective Studies; Sensitivity and Specificity
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.1249

The majority of colorectal cancers (CRC) harbor somatic mutations and epigenetic modifications in the tumor tissue, and some of these mutations can be detected in plasma as circulating tumor DNA (ctDNA). Precancerous colorectal lesions also contain many of these same mutations. This study examined plasma for ctDNA from patients undergoing a screening or diagnostic colonoscopy to determine the sensitivity and specificity of the ctDNA panel for detecting CRC and precancerous lesions. Two hundred patients without a history of nonskin cancer had blood drawn before a colonoscopy. Plasma ctDNA was measured with a 96 mutation panel for nine cancer driver genes. The ctDNA results were correlated with the findings at colonoscopy. Of the 200 patients, 176 (88%) had wild‐type DNA, 12 (6%) had mutations detected, and 12 (6%) had indeterminate results. Colonoscopy was normal in 80% of the patients and 20% were found to have polyps. No CRC was found in this study, precluding a determination of true‐positive rate for CRC detection. Our ctDNA panel was positive in 13.2% of patients with colonic polyps found at colonoscopy, while 4.7% of patients with normal colonoscopy also had ctDNA detected, which may represent ctDNA released from a benign process, an occult tumor, or an acquired somatic mutation from clonal hematopoiesis.